Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up

Regeneron Pharmaceuticals (REGN) significantly surpassed Q2 2025 consensus estimates, reporting adjusted EPS of $12.89 and total revenues of $3.7 billion, leading to an uptick in shares despite a year-to-date decline. The strong performance was primarily driven by robust sales of Eylea HD, increased Dupixent collaboration profits, and solid Libtayo sales, although legacy Eylea US sales plunged 39% due to competition. Strategically, REGN is expanding its pipeline with the accelerated FDA approval of Lynozyfic and the in-licensing of an obesity drug, while navigating anticipated regulatory delays for some Eylea HD applications and odronextamab due to issues at a key manufacturing site.

Analysis

Regeneron Pharmaceuticals reported a strong second quarter for 2025, significantly outperforming consensus estimates with an adjusted EPS of $12.89 versus an expected $8.03 and revenues of $3.7 billion against a $3.3 billion forecast. This performance, representing 12% EPS and 4% revenue growth year-over-year, was primarily driven by the successful commercialization of Eylea HD, which generated $393 million, and robust collaboration revenues from Sanofi's Dupixent, which saw global sales rise 22% to $4.3 billion. This growth effectively masked the sharp 39% year-over-year decline in legacy Eylea sales in the U.S. due to intense competition from Roche's Vabysmo and other affordability pressures. While the oncology drug Libtayo also beat estimates with a 27% sales increase, operational headwinds are emerging. Gross margin compressed to 86% from 89% due to manufacturing investments and write-offs. More critically, regulatory approvals for new Eylea HD applications and the oncology drug odronextamab are now delayed or rejected due to FDA inspection issues at a third-party manufacturing site, Catalent, introducing significant near-term uncertainty to the pipeline's execution. The company is actively diversifying through the recent accelerated approval of its oncology drug Lynozyfic and a strategic in-licensing of a GLP-1/GIP obesity drug, while also returning capital to shareholders via a $1.07 billion share repurchase during the quarter.

Key Decisions for Investors

• Investors should re-evaluate Regeneron based on the growth trajectory of Eylea HD, Dupixent, and its oncology portfolio, as Q2 results confirm this strategic transition is successfully offsetting the secular decline of the legacy Eylea franchise.
• It is critical to monitor for any resolution to the manufacturing issues at the Catalent facility, as this poses a material risk to near-term revenue by delaying key regulatory approvals for Eylea HD line extensions and the pipeline drug odronextamab.
• The in-licensing of a GLP-1/GIP obesity drug signals a significant long-term strategic pivot; this should be factored into valuation models as a high-potential but early-stage growth driver that will require substantial R&D investment.
• Consider the remaining $2.8 billion share repurchase authorization as a potential source of valuation support, particularly given the stock's significant underperformance relative to its industry year-to-date.